GlassScriptPhysician profile
Fanta Beretay
NPI 1801045695
$2,953.50
in general payments reported to CMS, 2019-2025
12 companies · $916 in 2025
The $916 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $750 · 2023: $859 · 2024: $289 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $778.58 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $432.54 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $424.82 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $316.88 | 2021-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $307.71 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.59 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $144.70 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $105.22 | 2021-2023 | Rexulti |
| Indivior INC. | $93.75 | 2021-2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $61.97 | 2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $55.30 | 2021-2022 | |
| Noven Therapeutics, LLC | $25.44 | 2022-2023 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanta Beretay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.